Michael Greicius, MD, MPH

The genetic variant APOE4, carried by one-fifth of the world’s people, substantially boosts Alzheimer’s risk. But scientists have been puzzled about how to reverse that risk: punch up the gene variant’s potency, or smack it down? Now we know, thanks to research funded by the Knight Initiative for Brain Resilience.

This week on From Our Neurons to Yours, we talk with Stanford neurologist Mike Greicius about his critique of new amyloid-clearing Alzheimer's drugs, and his optimism for the next wave of therapies currently in development.

The APOE4 genetic variant, carried by about 20% of people, significantly raises Alzheimer’s risk. But should we boost the gene’s potency or suppress it? A recent discovery by Knight Initiative affiliate, Mike Greicius, may provide the answers we need.

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease, but which also carry safety risks according to Knight Initiative for Brain Resilience affiliate Mike Greicius and others.